BMC Pulmonary Medicine最新文献

{"title":"Exploring the potential of German claims data to identify incident lung cancer patients.","authors":"Josephine Kanbach, Nikolaj Rischke, Sabine Luttmann, Ulrike Haug","doi":"10.1186/s12890-025-03740-8","DOIUrl":"10.1186/s12890-025-03740-8","url":null,"abstract":"<p><strong>Background: </strong>Real-world healthcare databases offer great potential for cancer research, but the valid identification of cancer patients is crucial for the suitability of a database in this regard. We aimed to assess the plausibility of an algorithm to identify incident lung cancer (LC) patients in German claims data.</p><p><strong>Methods: </strong>Using the German Pharmacoepidemiological Research Database (GePaRD; claims data from ∼ 20% of the German population) we applied a previously developed algorithm which identifies incident LC patients and classifies them into advanced and non-advanced. We calculated age-standardized incidence rates (ASIRs) per 100,000 for the years 2013-2018. Further, we assessed the ASIRs stratified by the deprivation index of the district of residence and determined age-standardized five-year absolute and relative survival. We stratified all analyses by sex.</p><p><strong>Results: </strong>Overall, we identified ∼ 9,500 - 10,500 incident LC patients per year. In 2018, (N = 10,625, mean age: 69.2 years in men) the proportion classified as advanced at diagnosis was 71.4%; the ASIRs of LC were 45 per 100,000 in men (9% lower than in 2013) and 27 per 100,000 persons in women (similar to 2013). ASIRs were lowest in persons living in areas with a low deprivation index. Age-standardized five-year absolute and relative survival rates, respectively, were 31% and 34% in women and 27% and 31% in men.</p><p><strong>Conclusions: </strong>The algorithm we applied to identify incident LC patients in German claims data yielded plausible results, supporting its validity.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"289"},"PeriodicalIF":2.6,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12203718/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144504853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Procalcitonin and biomarkers for stroke-associated pneumonia: a systematic review and meta-analysis.","authors":"Yuan Wang, Tingting Wang, Shouqin Hu, Yuntao Cheng, Chongyue Du, Guolong Xu","doi":"10.1186/s12890-025-03750-6","DOIUrl":"10.1186/s12890-025-03750-6","url":null,"abstract":"<p><strong>Background: </strong>Stroke-associated pneumonia (SAP) is a common and severe complication following stroke, significantly impacting recovery and outcomes. Early identification of biomarkers and development of predictive models are essential for SAP diagnosis and prevention. This study systematically evaluated the diagnostic value of procalcitonin (PCT) and other biomarkers for SAP and explored their integration into predictive models.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted by searching PubMed, Web of Science, and CNKI databases for studies published up to March 2023. Inclusion criteria focused on studies reporting biomarkers for SAP diagnosis and predictive models. Statistical analyses included pooled sensitivity, specificity, diagnostic odds ratio (DOR), and area under the receiver operating characteristic curve (AUC) using RevMan 5.4 and R software.</p><p><strong>Results: </strong>This meta-analysis included 11 studies with 1,478 patients and found that PCT levels were significantly elevated in SAP patients, particularly those with ischemic stroke (standardized mean difference [SMD] = 2.89, 95% confidence interval [CI] = 1.74-4.04). PCT demonstrated high diagnostic accuracy, with a pooled sensitivity of 0.84, specificity of 0.89, DOR of 48.78, and AUC of 0.91, outperforming other biomarkers like CRP and IL-6. Predictive models incorporating biomarkers improved risk stratification, though heterogeneity among studies underscores the need for standardization.</p><p><strong>Conclusions: </strong>PCT is a reliable biomarker for SAP diagnosis, offering high sensitivity and specificity. Combining PCT with predictive models can enhance risk assessment and early detection of SAP. Further research is necessary to refine prediction models and validate the clinical application of biomarkers across diverse populations. This study underscores the importance of biomarkers in guiding SAP prevention and management strategies.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"286"},"PeriodicalIF":2.6,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The clinical usefulness of neutrophil percentage/albumin ratio in predicting the one-month mortality in chronic obstructive pulmonary disease patients hospitalized with community-acquired pneumonia.","authors":"Sule Gul, Mehmet Atilla Uysal, Ayse Yeter, Ramazan Eren, Barıs Demirkol, Elif Yelda Ozgun Niksarlıoglu","doi":"10.1186/s12890-025-03757-z","DOIUrl":"10.1186/s12890-025-03757-z","url":null,"abstract":"","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"288"},"PeriodicalIF":2.6,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147314/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257362","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Central lung cancer: improving operability assessment through 3D modelling.","authors":"Lubomír Tulinský, Ján Hrubovčák, Martin Pieš","doi":"10.1186/s12890-025-03759-x","DOIUrl":"10.1186/s12890-025-03759-x","url":null,"abstract":"<p><strong>Background: </strong>The objective of this study was to develop a novel method for creating highly detailed three-dimensional physical models of lung lobes, incorporating tumour morphology and surrounding structures, with the aim of improving the assessment of operability for central lung tumours.</p><p><strong>Case presentation: </strong>A method was developed that uses standard computed tomography (CT) scans to mark the desired structures and generate a three-dimensional image for physical model creation. The generated STL files can be seamlessly integrated into virtual reality, allowing the sharing of selected CT scan data. Our approach has been successfully integrated into clinical practice, enabling multidisciplinary teams to make informed decisions for patients with central lung tumours. We have reduced the preparation time of physical models from 100 h to 18 h.</p><p><strong>Conclusions: </strong>The novel method, which employs 3D printing technology, has enhanced the assessment of operability for central lung tumours, thereby facilitating more precise decisions regarding patient management. This innovative approach has the potential to enhance patient outcomes by reducing complications and optimizing treatment planning.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"287"},"PeriodicalIF":2.6,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of irae characteristics on efficacy of consolidative immunotherapy following chemoradiotherapy in locally advanced NSCLC.","authors":"Xiufen Wang, Xuebing Fu, Qiaohong Liu, Juan Li, Yihui Ge, Jian Zhang, Shuyun Wang, Leirong Wang, Dahai Wang, Yanxin Sun, Yiling Gan, Haodong Sun, Zhen Wang, Yuping Sun, Aiqin Gao","doi":"10.1186/s12890-025-03742-6","DOIUrl":"10.1186/s12890-025-03742-6","url":null,"abstract":"<p><strong>Background: </strong>Consolidative PD-L1 inhibitors after concurrent chemoradiotherapy (cCRT) have become standard care in locally advanced non-small cell lung cancer (LA-NSCLC). However, the correlation between immune-related adverse event (irAE) characteristics and patient outcomes remains unclear.</p><p><strong>Methods: </strong>This retrospective study enrolled LA-NSCLC patients who received consolidative PD-L1 inhibitors after CRT at four cancer centers. Patients who received CRT alone were also included for comparison. Associations between irAE characteristics, frequency, timing, affected systems, and severity, and progression-free survival (PFS) and overall survival (OS) were assessed. Tumor immune microenvironment (TIME) features were analyzed to identify subpopulations at higher risk of severe irAEs.</p><p><strong>Results: </strong>Among 107 patients, 59 (55.1%) developed irAEs; 89.8% were grade 1-2 and 10.2% grade 3-4. Patients with irAEs had significantly longer PFS than those without. Late-onset, single-system, endocrine, and mild irAEs predicted better PFS. In contrast, patients with severe irAEs had worse survival than those without ICI consolidation. TIME analysis revealed that severe irAEs were associated with higher CD103⁺CD8⁺ T cells infiltration. A > 1.545% cutoff for CD103⁺CD8⁺ T cells may help identify patients less likely to benefit from PD-L1 inhibitor consolidation.</p><p><strong>Conclusions: </strong>Occurrence of irAEs, particularly late-onset, single-system, or grade 1-2 correlated with greater benefit from consolidative PD-L1 inhibitors in LA-NSCLC. Conversely, severe irAEs predict poorer survival, even compared to no ICI consolidation. Elevated CD103⁺CD8⁺ T cell infiltration may serve as a biomarker to identify patients at risk of severe irAEs who may not benefit from immunoconsolidation therapy.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"283"},"PeriodicalIF":2.6,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144761/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246380","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of pressure support ventilation duration after a spontaneous breathing trial on reintubation rates in critically ill subjects: a retrospective study.","authors":"Jinlong Xu, Zefang Liu, Simei Wang, Zhenghua Liang, Qiuyu Liu, Zhihua Xu, Pingzhen Wu, Lijun Liang","doi":"10.1186/s12890-025-03744-4","DOIUrl":"10.1186/s12890-025-03744-4","url":null,"abstract":"<p><strong>Background: </strong>To investigate the effect of different durations of pressure support ventilation (PSV) after a spontaneous breathing trial (SBT) on 48-hour reintubation rates in critically ill subjects.</p><p><strong>Methods: </strong>This single-center retrospective cohort study included adult subjects who received mechanical ventilation for over 48 h, successfully completed SBT, and were scheduled for extubation in the intensive care unit of a tertiary hospital between January and December 2023. Subjects were divided into three groups based on PSV duration after SBT: direct extubation (DE, ≤ 30 min), short-term PSV (SP, 30 min-3 h), and long-term PSV (LP, 3-12 h). The primary outcome was the 48-hour reintubation rate. The secondary outcomes included intensive care unit length of stay and 28-day mortality.</p><p><strong>Results: </strong>A total of 982 subjects were included (638, 235, and 109 in the DE, SP, and LP groups, respectively). The 48-hour reintubation rates were 18.34%, 14.04%, and 16.51% in the DE, SP, and LP groups, respectively (P = 0.298). Multivariate logistic regression showed no significant difference in reintubation risk for SP (OR = 0.73, P = 0.141) and LP groups (OR = 0.88, P = 0.643) compared with the DE group. Age (OR = 1.18, P = 0.003) and APACHE II score (OR = 1.07, P < 0.001) were identified as independent risk factors for reintubation. The median intensive care unit length of stay was 16 days in the DE group, 18 days in the SP group, and 19 days in the LP group (P = 0.033). The 28-day mortality did not differ significantly among groups (12.85%, 11.91%, and 14.68%, respectively; P = 0.690).</p><p><strong>Conclusions: </strong>PSV duration after SBT did not significantly affect reintubation rates in the overall population. While short-term PSV showed potential benefits in specific subgroups, particularly COPD patients, direct extubation after successful SBT appears safe for most patients and may reduce ICU length of stay. These findings suggest that extubation strategies should be individualized based on patient characteristics rather than applying extended PSV periods universally.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"285"},"PeriodicalIF":2.6,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144731/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Age-differentiated comparison of health-related quality of life and impacting factors in patients with COPD receiving long-term home non-invasive ventilation.","authors":"Maximilian Zimmermann, Franziska Vocht, Doreen Kroppen, Daniel S Majorski, Melanie P Berger, Sarah B Stanzel, Johannes F Holle, Falk Schumacher, Tim Matthes, Wolfram Windisch, Maximilian Wollsching-Strobel","doi":"10.1186/s12890-025-03737-3","DOIUrl":"10.1186/s12890-025-03737-3","url":null,"abstract":"<p><strong>Background: </strong>Non-invasive ventilation (NIV) is a well-established treatment for chronic hypercapnic respiratory failure (CHRF). While studies have demonstrated benefits for mortality, hospitalization rates, and health related quality of life (HRQL), evidence is particularly sparse regarding HRQL determinants in the older population.</p><p><strong>Methods: </strong>In a prospective, monocentric observational study, HRQL was assessed using the established Severe Respiratory Insufficiency Questionnaire (SRI). The study was prospectively registered in the German Clinical Trials Register on 17 June 2015 under the registration number DRKS00008759. Patients were categorized into two age-based groups: older patients (≥ 65 years) and younger patients (< 65 years). Multiple linear regression analyses were used to analyze factors on HRQL, including SRI scores, anemia, autonomy impairment, exacerbation history and other factors.</p><p><strong>Results: </strong>237 Patients with COPD with CHRF receiving NIV therapy were included. The mean SRI summary score was 49.9 ± 16.8. with 23.2% (N = 55) suffering from anemia and 36.7% (N = 87) experiencing ≥ 2 exacerbations annually. Autonomy impairment was observed in 49.4% (N = 117) of patients. The updated Charlson Comorbidity Index (uCCI) was 2.2 ± 1.86. No significant differences were found in SRI Summary Scale scores between age groups (p = 0.581), but notable disparities were present in the uCCI (p = 0.014). Multiple regression analysis revealed a negative association of exacerbation history (Young group: -9.2; 95% CI = -14.8/ -3.55 vs. Older group: -6.17; 95% CI = -11.91/ -0.43) and level of autonomy impairment (e.g. Level of Care 2 Young group: -13.91; 95% CI = -21.4/ -6.43 vs. Older group: -14.94; 95% CI = -22.64/ -7.24) on SRI scores with age-related differences. Anemia only had a negative association on the SRI scores in younger patients with COPD (Young group: -7.9; 95% CI = -14.0/ -1.75 vs. Older group: -1.78; 95% CI = -9.21/ 5.65).</p><p><strong>Discussion: </strong>Frequent exacerbations and a higher level of autonomy impairment had a negative association on HRQL across all ages. However only higher levels of impairment (≥ 2) have a detrimental impact on older patients. Anemia was a negative HRQL factor in younger patients, where it was more prevalent. Overall, HRQL was found to be comparably favorable in both older and younger patients, despite age-specific differences in influencing factors.</p><p><strong>Registration of the clinical trial: </strong>The study from which the data were analyzed was prospectively registered in the German Clinical Trials Register (DRKS00008759) on June 17, 2015.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"284"},"PeriodicalIF":2.6,"publicationDate":"2025-06-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144842/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Lung Cancer incidence in both sexes across global areas: data from 1978 to 2017 and predictions up to 2035.","authors":"Dong-Ning Lu, Yan Jiang, Wan-Chen Zhang, Rong-Kang Du, Ao Zeng, Yi-Mu Wu, Xiao Zhou","doi":"10.1186/s12890-025-03748-0","DOIUrl":"10.1186/s12890-025-03748-0","url":null,"abstract":"<p><strong>Background and aim: </strong>Lung cancer (LC) is one of the most prevalent and fatal malignancies worldwide. With the progress of society, the pathogenic factors, medical diagnosis, and environmental health policies of lung cancer have all changed. Therefore, predicting the incidence trend of LC is of significance for people to understand the future burden of LC.In this study, we aimed to analyze temporal trends in LC incidence across 45 areas from 1978 to 2017, investigate regional and demographic patterns of LC incidence, and predict trends from 2018 to 2035.</p><p><strong>Methods: </strong>Data on annual LC cases and population statistics, stratified by age and sex, were collected from 111 cancer registries in 45 areas across five continents using the Cancer Incidence in Five Continents Plus database. From 1978 to 2017, age-standardized rates (ASRs) per 100,000 individuals were calculated for both sexes and different age groups. A Bayesian age-period-conhort (BAPC) model was applied to forecast ASRs until 2035.</p><p><strong>Results: </strong>From 1978 to 2017, LC ASRs decreased in most areas for men (32/45 areas) but increased for women (37/45 areas), and mainly due to the rising incidence rate among elderly women (> 60 years old). Among men, the country with the largest increase was Cyprus (+ 71.95%), and the largest decrease was Costa Rica (-64%). Among women, France saw the greatest increase (+ 515.15%) while Kuwait had the least (-72.85%). In addition, the LC ASR in high-income areas is higher than that in middle - and low-income areas. However, projections from 2018 to 2035 suggested that only 8 of 45 areas will witness increasing LC ASRs for men, whereas 18 areas will experience ASR increases for women.</p><p><strong>Conclusion: </strong>Overall, global LC incidence is gradually declining. However, considerable disparities exist across areas, sexes, and developmental stages. Therefore, understanding area-specific trends, customizing control measures to local contexts, and conducting screening and early interventions in high-incidence areas and populations are central to overcoming these differences.</p><p><strong>Clinical trial number: </strong>Not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"281"},"PeriodicalIF":2.6,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135282/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Causal association between plasma proteins and lung adenocarcinoma: a two-sample mendelian randomization study.","authors":"Weiyuan Zhang, Nan Chen, Changxi Li, Xitian Su, Zhuo Fu, Youshuang Zhong, Huojin Deng","doi":"10.1186/s12890-025-03751-5","DOIUrl":"10.1186/s12890-025-03751-5","url":null,"abstract":"<p><strong>Background: </strong>This study utilized Mendelian randomization (MR) to investigate the causal relationship between circulating plasma proteins and lung adenocarcinoma.</p><p><strong>Methods: </strong>We obtained 734 circulating plasma protein data from genome-wide association studies (GWAS) as exposure factors and extracted single nucleotide polymorphisms (SNPs) as instrumental variables. And we obtained lung adenocarcinoma data (including 11,245 cases and 54,619 controls) from the IEU Open GWAS database as the outcome factor. The main analytical methods used are inverse-variance weighted (IVW) or Wald ratio to assess the causal relationship between circulating plasma protein levels and lung adenocarcinoma. Sensitivity analysis (leave one out method, heterogeneity and pleiotropy tests), external validation analysis, and meta-analysis after MR were used to evaluate the reliability of MR results. Finally, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed on the final screened plasma proteins.</p><p><strong>Results: </strong>Through the preliminary and external validation stages, ICAM5 (OR = 0.92, 95%CI: 0.89-0.95, P = 2.31 × 10^-6), PCYOX1 (OR = 0.89, 95%CI: 0.85-0.93, P = 5.31 × 10^-8), and TYMP (OR = 0.76, 95%CI: 0.66-0.87, P = 5.79 × 10^-5) are negatively correlated with lung adenocarcinoma. Sensitivity analyses, external validation, and post-MR meta-analysis indicated that the MR results were robust. GO and KEGG pathway enrichment analyses demonstrated that these plasma proteins were primarily enriched in pathways such as \"pyrimidine deoxyribonucleoside monophosphate metabolic process\", \"deoxyribonucleoside monophosphate catabolic process\", \"mitochondrial genome maintenance\", and \"Pyrimidine metabolism\".</p><p><strong>Conclusions: </strong>ICAM5, PCYOX1 and TYMP are associated with a decreased risk of lung adenocarcinoma. Plasma proteins may become new biological markers for lung adenocarcinoma, providing new insights into the prevention and treatment of this disease.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"280"},"PeriodicalIF":2.6,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12135537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The triple overlap of COPD, severe obesity, and high risk of OSA: insights from an NHANES analysis.","authors":"Staci L Orbell, Jonna L Morris, Paul W Scott, Lynn M Baniak, Christopher C Imes, Bomin Jeon, Weiwen Wang, Yue Dong, Patrick J Strollo, Faith S Luyster","doi":"10.1186/s12890-025-03752-4","DOIUrl":"10.1186/s12890-025-03752-4","url":null,"abstract":"<p><strong>Purpose: </strong>With the rising prevalence of severe obesity, the coexistence of obstructive sleep apnea (OSA) and chronic obstructive pulmonary disease (COPD) often progresses to triple overlap syndrome, a condition with significant health implications. However, its prevalence remains poorly understood. Using population-based data from the National Health and Nutrition Examination Survey (NHANES), we examined the prevalence of triple overlap of COPD, severe obesity, and high risk for OSA (HR-OSA) and associated sociodemographic factors among US adults.</p><p><strong>Methods: </strong>A cross-sectional analysis was performed using NHANES data between 2005 and 2008 and 2015-March 2020. COPD diagnosis was collected via self-report questionnaire. HR-OSA was determined by an adapted Multivariable Apnea Prediction index. Severe obesity was defined as a body mass index of ≥ 40.0 kg/m².</p><p><strong>Results: </strong>From 2005 to 2008 to 2015-March 2020, the proportion of participants with triple overlap of COPD, severe obesity, and HR-OSA increased from 0.653% (95% CI, 0.651-0.655%) to 1.560% (95% CI, 1.557-1.563%). During the same period, the increase in the age-standardized prevalence of severe obesity (from 6.298% [95% CI, 6.291-6.305%] to 8.943% [95% CI, 8.936-8.950%]) and HR-OSA (from 58.667% [95% CI, 58.646-58.688%] to 58.776% [95% CI, 58.758-58.794%]; ) exceeded the increase for COPD (from 9.223% [95% CI, 9.215-9.231%] to 10.213% [95% CI, 10.206-10.220%]). Women and those with low family income were more likely to have triple overlap of COPD, severe obesity, and HR- OSA.</p><p><strong>Conclusion: </strong>The triple overlap of COPD, severe obesity, and HR-OSA significantly increased among US adults over the past 15 years, with disparities across different sociodemographic groups.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":9148,"journal":{"name":"BMC Pulmonary Medicine","volume":"25 1","pages":"282"},"PeriodicalIF":2.6,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12139052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144224292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}